Expression of gremlin, a gene involved in nephrogenesis, may not end after embryonic development and can reemerge in the context of diabetic nephropathy.
Read More »Study Shows Increased Risk of Common Infections With Diabetes
People with type 1 or type 2 diabetes are at higher risk of contracting respiratory, urinary tract and skin infections than people without diabetes.
Read More »Valsartan Vs. Amlodipine in Prevention of Type 2 Diabetes
Valsartan is significantly superior to amlodipine for prevention of new-onset type-2 diabetes in high-risk patients with hypertension.Tesaglitazar Shows Promise in
Read More »Metformin Plus Insulin improves Glycemic Control and Reduces Weight Gain
Type 2 patients who require insulin treatment, continuing metformin treatment reduced weight gain and insulin requirement, and improved glycemic control.
Read More »Oral Insulin Spray May Offer Preprandial Advantages
Simplicity of an oral insulin spray “will facilitate acceptance and increase use by primary care physicians and patients alike.
Read More »When Combined With Metformin, Premixed Insulin Analogue Is More Effective
Than Glargine Reduction in A1c was significantly better in the premixed insulin aspart group then in the glargine group
Read More »Beta-Cells Regenerate Even In Type 1 Diabetes
A new study provides evidence that the pancreas continues to form beta cells even in the setting of long-standing type 1diabetes.
Read More »DCCT Continues To Provide New Data:
CVD Events Lowered by 60% Years Later for Intensive Group. By following the participants in the DCCT study since it’s conclusion in 1993, it has continued to provide new information. For the first time, intensive treatment of diabetic patients results in a significantly lower risk of heart disease by 57%.
Read More »Positive Results with Novo Nordisk A/S Long-Acting GLP-1 Analog and Gastrin Comb
Combination brings back normal blood glucose levels by increasing beta-cell mass.
Read More »FDA Approves Levemir(R) (insulin detemir [rDNA Origin] Injection)
A New, Long-Acting Insulin Treatment for Diabetes. Denmark’s Novo Nordisk said on Friday the United States Food and Drug Administration (FDA) has approved its long-acting 24 hr. insulin for treatment of diabetes.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.